| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.28 | 5e-07 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.24 | 2e-06 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.17 | 9e-06 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.17 | 5e-05 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | -0.17 | 8e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0001 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0003 |